'Itt population' presentation slideshows

?????? LM ????

?????? LM ????. ??????? ???????? ??? MD, PhD, FACC. TCC 2009,09/06/23-26 ??. ????. ??????? TFI ???? TRI ??? TRI ????? TRI ?? LM ???? TRI ?? LM ???????. TFI ?????. ???? 24 ??????? ?? DVT+ ???????? ???????????????? ?????????? ????????? ??? <3ms ??????

1.75k views • 150 slides

944 views • 63 slides

Division of Oncology Drug Products Presentation NDA 21-649 Genasense (Oblimersen) for metastatic melanoma ODAC May

Division of Oncology Drug Products Presentation NDA 21-649 Genasense (Oblimersen) for metastatic melanoma ODAC May 3, 2004. Project Management Nicholette Hemingway, MPH Medical Review Robert Kane, MD Ann Farrell, MD Statistical Review Peiling Yang, Ph.D.

825 views • 54 slides

Meningococcal A,C,Y,W135 Conjugate Vaccine (Menactra TM )

Aventis Pasteur, Inc. Meningococcal A,C,Y,W135 Conjugate Vaccine (Menactra TM ). Lucia H. Lee CBER, FDA. Vaccines and Related Biological Products Advisory Committee Meeting September 22, 2004. Outline. Proposed Basis for Licensure: 11-55 years old Clinical Studies

805 views • 48 slides

505 views • 36 slides

Richard A. Larson, Philipp le Coutre, Josy Reiffers, Timothy Hughes, Giuseppe Saglio, Pascal Edrich, Albert Hoenekopp, Neil Gallagher, Hagop Kantarjian, Andreas Hochhaus on behalf of the ENESTnd Investigators.

587 views • 28 slides

Richard A. Larson, Philipp le Coutre, Josy Reiffers, Timothy Hughes, Giuseppe Saglio, Pascal Edrich, Albert Hoenekopp, Neil Gallagher, Hagop Kantarjian, Andreas Hochhaus on behalf of the ENESTnd Investigators.

389 views • 28 slides

365 views • 25 slides

Welcome to the 6 th European Bifurcation Club 22-23 October 2010 - BUDAPEST

Welcome to the 6 th European Bifurcation Club 22-23 October 2010 - BUDAPEST. Summary of Left Main Stem publications since last EBC Alaide Chieffo, MD San Raffaele Scientific Institute Milan, Italy . No conflict to declare. CONFLICT OF INTEREST t.

248 views • 24 slides

337 views • 18 slides

Introduction

Tenofovir DF + Efavirenz (TDF+EFV) vs Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial.

302 views • 16 slides

Introduction

Tenofovir DF + Efavirenz (TDF+EFV) vs Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial.

163 views • 16 slides

Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for stage III colon cancer: Final results of NO16968

Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for stage III colon cancer: Final results of NO16968. H-J. Schmoll, J. Tabernero, J. Maroun, F. de Braud T. Price, E. Van Cutsem, M. Hill, S. Hoersch K. Rittweger, D. Haller. Background.

544 views • 10 slides

Disease Activity at 52 Weeks (ITT population)

Disease Activity at 52 Weeks (ITT population). Radiographic Progression at 52 Weeks (ITT population). Week 24: Overall ITT Population.

102 views • 3 slides

557 patients included in the ITT efficacy analysis 555 assessed for EGFR expression

1861 patients screened 1688 with tumors suitable for EGFR expression assessment. 321 excluded 183 did not meet inclusion criteria 79 refused to participate 59 other reasons. 1442 patients with EGFR-expressing tumors. 4 EGFR status unknown. 1125 randomly assigned ITT population.

183 views • 1 slides

P394

Introduction.

77 views • 1 slides